

<https://helda.helsinki.fi>

Activation of histamine H-3 receptor decreased cytoplasmic Ca²⁺ imaging during electrical stimulation in the skeletal myotubes

Chen, Yan

2015-05-05

Chen , Y , Paavola , J , Stegajev , V , Stark , H , Chazot , P L , Wen , J G & Konttinen , Y T
2015 , ' Activation of histamine H-3 receptor decreased cytoplasmic Ca²⁺ imaging during
electrical stimulation in the skeletal myotubes ' , European Journal of Pharmacology , vol.
754 , pp. 185-190 . <https://doi.org/10.1016/j.ejphar.2015.02.035>

<http://hdl.handle.net/10138/223806>

<https://doi.org/10.1016/j.ejphar.2015.02.035>

publishedVersion

Downloaded from Helda, University of Helsinki institutional repository.

This is an electronic reprint of the original article.

This reprint may differ from the original in pagination and typographic detail.

Please cite the original version.



Molecular and cellular pharmacology

Activation of histamine H₃ receptor decreased cytoplasmic Ca²⁺ imaging during electrical stimulation in the skeletal myotubes

Yan Chen^{a,b,c}, Jere Paavola^d, Vasili Stegajev^{b,c}, Holger Stark^e, Paul L. Chazot^f,
Jian Guo Wen^{a,*}, Yrjö T. Konttinen^{b,g,h,**}

^a Department of Urology, Institute of Clinic Medicine, the First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052 China

^b Department of Medicine, Helsinki University Central Hospital, Biomedicum 1, PO Box 700, FIN-00029 Helsinki, Finland

^c Department of Anatomy, University of Helsinki, Biomedicum 1, PO Box 63, FIN-00029 Helsinki, Finland

^d Unit of Cardiovascular Research, Minerva Foundation Institute for Medical Research, Biomedicum Helsinki 2U, Tukholmankatu 8, 00290, Helsinki, Finland

^e Goethe University, Institute of Pharmaceutical Chemistry, ZAFES/OSF/NeFF, Max-von-Laue-Str. 9, 60438 Frankfurt am Main, Germany

^f School of Biological & Biomedical Sciences, Durham University, South Road, Durham DH1 3LE, Durham, UK

^g ORTON Orthopedic Hospital of the ORTON Foundation, Tenholantie 10, 00280 Helsinki, Finland

^h COXA Hospital for Joint Replacement, Biokatu 6 B, 33520 Tampere, Finland

ARTICLE INFO

Article history:

Received 15 October 2014

Received in revised form

2 February 2015

Accepted 15 February 2015

Available online 3 March 2015

Keywords:

Skeletal myogenesis

Histamine H₃ receptor

Calcium

Skeletal myotubes

Electrical stimulation

ABSTRACT

Histamine is a neurotransmitter and chemical mediator in multiple physiological processes. Histamine H₃ receptor is expressed in the nervous system, heart, and gastrointestinal tract; however, little is known about H₃ receptor in skeletal muscle. The aim of this study was to investigate the role of H₃ receptor in skeletal myotubes. The expression of H₃ receptor and myosin heavy chain (MHC), a late myogenesis marker, was assessed by real-time PCR and immunostaining in C2C12 skeletal myogenesis and adult mid-urethral skeletal muscle tissues. H₃ receptor mRNA showed a significant increase upon differentiation of C2C12 into myotubes: 1-, 26-, 91-, and 182-fold at days 0, 2, 4, and 6, respectively. H₃ receptor immunostaining in differentiated C2C12 cells and adult skeletal muscles was positive and correlated with that of MHC. The functional role of H₃ receptor in differentiated myotubes was assessed using an H₃ receptor agonist, (R)-α-methylhistamine ((R)-α-MeHA). Ca²⁺ imaging, stimulated by electric pacing, was decreased by 55% after the treatment of mature C2C12 myotubes with 1 μM (R)-α-MeHA for 10 min and 20 min, while treatment with 100 nM (R)-α-MeHA for 5 min caused 45% inhibition. These results suggested that H₃ receptor may participate in the maintenance of the relaxed state and prevention of over-contraction in mature differentiated myotubes. The elucidation of the role of H₃R in skeletal myogenesis and adult skeletal muscle may open a new direction in the treatment of skeletal muscle disorders, such as muscle weakness, atrophy, and myotonia in motion systems or peri-urethral skeletal muscle tissues.

© 2015 Elsevier B.V. All rights reserved.

1. Introduction

Histamine is a well-known biogenic cationic amine that is synthesized, stored, and released by professional histamine-synthesizing cells, such as mast cells, basophils, and enterochromaffin cells. These cells express histidine decarboxylase, which

effectively converts L-histidine to histamine (Ichikawa et al., 2010). Histamine plays an important role as an inflammatory mediator and neurotransmitter and exerts its effects by binding to G protein-coupled histamine receptors H₁–H₄ receptor with different affinities. H₁ receptor (pK_i for histamine 4.2) and H₂ receptor (pK_i for histamine 4.3) have long been established as histamine receptors that are expressed in various tissues (Walter and Stark, 2012), but in the last decades, H₃ receptor and H₄ receptor, which have a higher affinity for histamine (pK_i 8.0 and 8.2, respectively), have been characterized mostly in non-professional histamine-producing cells, such as dendritic cells and lymphocytes (Szeberenyi et al., 2001 and Kubo and Nakano, 1999). The data obtained using HR agonists and/or antagonists have suggested that H₄ receptor is mainly involved in immunity and is expressed in immune cells, while H₃ receptor has been reported to be

* Corresponding author at: Institute of Clinic Medicine, the First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052 China. Tel.: +86 371 66295228; fax: +86 371 66970906.

** Corresponding author at: Institute of Clinical Medicine, Department of Medicine, Biomedicum 1, PO Box 700, FIN-00029 Helsinki, Finland. Tel.: +358 9 191 25210; fax: +358 9191 25218.

E-mail addresses: wenjg@hotmail.com (J.G. Wen), yrjokonttinen@sina.com (Y.T. Konttinen).

expressed in the brain and presynaptic membranes of myoneural junctions (Zampeli and Tiligada, 2009 and Leurs et al., 2005). H₃ receptor activation with a selective agonist in the cardiac sympathetic nerve endings reduced the rise in intracellular Ca²⁺ concentration in response to membrane depolarization, while a selective H₃ receptor antagonist inhibited this effect (Silver et al., 2002). Some studies have also found functional H₃ receptor expressed in smooth muscle cells, such as bronchial smooth muscle cells (Cardell and Edvinsson, 1994) and bladder detrusor cells (Neuhaus et al., 2006). However, there has been no information on H₃ receptor expression in skeletal muscle cells, myoblasts, or myotubes, and, consequently, on the role of H₃ receptor in skeletal myogenesis.

The presence and functional role of H₃ receptor in smooth muscle cells led us to hypothesize that H₃ receptor may also be expressed in skeletal muscles, where it may play a role in cytoplasm and calcium regulation of the myotubes.

2. Materials and methods

2.1. Cell culture

Mouse C2C12 myoblasts were obtained from the Turku Center for Biotechnology, University of Turku, Finland (Pallari et al., 2011), and were maintained in Dulbecco's Modified Eagle's Medium (DMEM, Lonza/BioWhittaker, Walkersville, MD, USA) supplemented with 10% fetal bovine serum (FBS; HyClone, Boston, MA, USA), antibiotics, and L-glutamine, at 37 °C in a humidified 5% CO₂ atmosphere. The differentiation medium had the same composition, except that FBS was reduced to 1%. The cells were passaged at 80% confluence using trypsinization with 0.5% trypsin in 0.5 mM EDTA (Gibco BRL, Life Technologies, Gaithersburg, MD, USA). Three parallel samples were cultured concurrently.

2.2. Quantitative reverse transcription-polymerase chain reaction (qRT-PCR)

To investigate the expression of H₃ receptor during C2C12 myogenesis, 5 × 10⁴ cells/well were seeded in 12-well plates (CellStar, Greiner Bio-One, Frickenhausen, Germany) in 10% FCS-containing DMEM for 2 days. After reaching 80% confluence, cell monolayers were switched to the differentiation medium to induce myogenesis. Total RNA was isolated from C2C12 cells at days 0, 2, 4, and 6 using the RNeasy Mini Kit (QIAGEN, Düsseldorf, Germany) according to the manufacturer's instructions, and 1 µg of total RNA was reverse-transcribed using the iScript cDNA Synthesis Kit (BioRad Laboratories, Hercules, CA, USA). qRT-PCR was performed with 100 ng first-strand cDNA as a template, using iQ SYBR Green Supermix (Bio-Rad) and an iCycler iQ5 Multicolor Real-Time PCR Detection System (Bio-Rad). Primers for the genes encoding mouse myosin heavy chain IIa (MHC-IIa) (forward: 5'-AGTCGACCTTCTCGTTTGCCA-3'; reverse: 5'-CGGTCAGGTCGCTCCTGCT-3'; amplicon size 261 bp), H₃ receptor (forward: 5'-TTCCGAGCTCCGACCCAGAA-3', reverse: 5'-GGTCCAACGGCCGGT-CAGC-3'; amplicon size 118 bp) and porphobilinogen deaminase (PBGD) (forward: 5'-AAAGTGCCGTGGGAACCAGC-3', reverse: 5'-CAGCCACAGCCAGGACGATG-3'; amplicon size 156 bp) were designed using the NCBI Primer BLAST program. The mRNA copy numbers in the samples were determined in triplicate and were normalized against that of PBGD. The results were analyzed using the comparative CT method and the expression levels of the cells of each individual were normalized to the expression of D0.

2.3. Immunofluorescence

C2C12 cells were seeded at a density of 2 × 10⁴ cells/well on coverslips in 24-well plates (Cell Star, Sigma-Aldrich, St Louis, MO, USA) and allowed to grow in DMEM with 10% FCS for 2 days to reach 80% confluence; then, the cells were switched to differentiation medium to induce myogenesis. The cells from differentiation days 0 and 6 were fixed in 4% paraformaldehyde in 10 mM phosphate-buffered 140 mM saline (PBS, pH 7.4) for 15–20 min, washed three times for 5 min in PBS and permeabilized in 0.5% Triton X-100 in PBS for 15 min. Cells were blocked with 10% normal donkey serum (Jackson ImmunoResearch Laboratories, Inc., West Grove, PA, USA) for 1 h and incubated at 4 °C overnight with 1 µg/ml of primary antibodies: polyclonal affinity-purified rabbit anti-human MHC IgG (a gift of Dr. John E. Erikson, University of Turku, Turku, Finland) (Pallari et al., 2011), rabbit anti-human H₃ receptor polyclonal antibodies (LS-A476, MBL International, Woburn, MA, USA), or non-immune rabbit IgG (R&D Systems, Minneapolis, MN, USA) was used as negative control. Cells were washed three times for 5 min in PBS and incubated with Alexa Fluor[®] 488-conjugated donkey anti-rabbit IgG (Invitrogen, Carlsbad, CA, USA) diluted 1:400 in 0.1% BSA–PBS for 1 h, washed three times for 5 min in PBS each time, and counterstained with 4', 6-diamidino-2-phenylindole (DAPI) (Sigma-Aldrich, St. Louis, MO, USA) diluted 1:2000 in distilled water, for 5 min. The coverslips were washed quickly twice in PBS and distilled water for 10 min before mounting with Vectashield (Vector Laboratories Inc., Burlingame, CA, USA). Labeled slides were photographed using a Leica DM 6000 B/M fluorescence microscope equipped with a motorized Leica XY-stage and connected to a Leica DFC 420 digital camera (Leica Microsystems, Wetzlar, Germany) and analyzed using the Leica Application Suite Advanced Fluorescence 2.5.0.6735 software.

2.4. Immunohistochemistry

The study protocol was approved by the institutional Medical Ethics Committee and was in accord with the 1983 Declaration of Helsinki. Informed consent was obtained from all volunteers.

The mid-urethral striated muscle samples were obtained from three healthy male volunteers by biopsy. The samples were fixed in 40% formaldehyde solution for 24 h and embedded in paraffin. Paraffin blocks were sliced into 3–5-µm sections, which were placed on the slides and incubated at 37 °C overnight. Samples were deparaffinized by using xylene and antigens were retrieved by heating samples in a microwave in 10 mM citrate buffer, and were then incubated in 1% hydrogen peroxide to quench endogenous peroxidase activity. The samples were stained using a VECTASTAIN Elite ABC Kit (Rabbit IgG) (PK-6101, Vector Laboratories, Burlingame, CA, USA). The slides were blocked in 10% normal donkey serum for 1 h and incubated at 4 °C overnight with 1 µg/ml of primary antibodies, viz., polyclonal affinity-purified rabbit anti-human MHC IgG, rabbit anti-human H₃ receptor polyclonal antibodies, or non-immune rabbit IgG used as negative control. The slides were washed three times for 5 min in PBS and were then incubated with the secondary donkey anti-rabbit IgG diluted 1:400 in 0.1% BSA–PBS for 1 h. After washing three times for 5 min in PBS, the slides were incubated with the ABC complex for 1 h, washed three times for 5 min in PBS, and were then incubated in the peroxidase substrate solution until the desired staining intensity appeared (maximum time: 10 min). The slides were then washed in distilled water, counterstained in Mayer's hematoxylin, washed in running water, dehydrated in graded ethanol, and cleared in xylene before being mounted in Vectashield.

2.5. Cytoplasmic Ca^{2+} imaging

C2C12 cells were differentiated for 7 days into myotubes on 18-mm coverslips. The cells were then loaded with 4 $\mu\text{mol/L}$ Fluo-4 AM Ca^{2+} indicator dye (F-14201, Invitrogen, Carlsbad, CA, USA) for 30 min at room temperature in Elliot medium, containing (mM): 137 NaCl, 5 KCl, 0.44 KH_2PO_4 , 20 HEPES, 4.2 NaHCO_3 , 5 D-glucose, 2 CaCl_2 , 1.2 MgCl_2 , and 1 Na-pyruvate (pH adjusted to 7.4 with NaOH). Then, a 30-min de-esterification was performed at 37 °C and the coverslips were transferred to an RC-49MFS recording chamber equipped with electrodes for field stimulation (Warner Instruments Inc., Hamden, CT, USA) and maintained at 37 °C during imaging.

H_3 receptor agonist R-(α)-methylhistamine ((R)- α -MeHA), at different concentrations (1 nM, 10 nM, 100 nM, 1 μM , 10 μM , and 100 μM) in Elliot medium, and a blank control (Elliot medium) were added into parallel coverslip chambers for 5, 10, 20 min, and 30 min before electrical pacing. Ca^{2+} imaging in the cytoplasm was recorded during stimulation. The cells were electrically paced at a frequency of 0.5 Hz with 10-ms bipolar pulses (200–360 mA) using a SIU-102 Stimulus Isolation Unit (Warner Instruments, Hamden, CT, USA) connected to a Master-8 stimulator (A.M.P.I., Jerusalem, Israel). Ca^{2+} imaging was observed under an inverted IX70 microscope (Olympus Corporation, Hamburg, Germany) equipped with transparent housing, a heater, and a temperature control unit (Solent Scientific, Ltd, Segensworth, UK) using a UPlanSApo 20 \times air objective (Olympus Corporation, Hamburg, Germany). Polychrome IV (TILL Photonics, Graefelfing, Germany) was used to illuminate the sample at a wavelength of 488 nm; emitted light was filtered through a Chroma filter set (EM HQ535/50 m, BS Q505LP, Chroma Technology Corporation, Bellows Falls, VT, USA). Images were recorded with a Hamamatsu ORCA-Flash 4.0 sCMOS camera (Hamamatsu Photonics K.K., Hamamatsu,

Japan) at 50 frames/s. Data acquisition was controlled and the recordings were analyzed using HC Image software (Hamamatsu Photonics K.K., Hamamatsu, Japan). The cells for analysis were manually selected in the regions of interest and the background was subtracted before quantifying the fluorescence relative to baseline fluorescence (F/F_0).

2.6. Statistical analysis

All values are given as mean \pm standard error of the mean (S.E.M.). Statistical differences were evaluated using the Mann–Whitney test (Matlab, MathWorks Inc., Natick, MA, USA).

3. Results

3.1. C2C12 cell morphology during myogenesis

Before differentiation, C2C12 cells presented as mononuclear myoblasts around 10- μm in diameter, round or spindle-like; they were well spread and showed many contacts with the substrate (Fig. 1A). When the cells were induced to differentiate, they started proliferating and migrating and then arranged themselves along a single direction to fuse into myotubes. After 6 days of differentiation, the cells fused into long, multinucleated myotubes of over 150- μm in diameter (Fig. 1B).

3.2. H_3 receptor expression during myogenesis and in human mid-urethral striated muscles

The expression of H_3 receptor and the late myogenesis marker MHC during C2C12 differentiation was assessed using qRT-PCR. MHC increased over the course of differentiation by 7168-, 89487-




Fig. 1. C2C12 cell differentiation and H_3 receptor expression. C2C12 cells grown in 10% fetal calf serum (FCS)-containing DMEM were switched to 1% FCS DMEM and differentiated for 6 days. The expression of H_3 receptor and MHC (a differentiation marker) was assessed by quantitative reverse transcription-polymerase chain reaction (qRT-PCR). (A) C2C12 myoblasts at differentiation day 0; (B) C2C12 myotubes at differentiation day 6; (C) H_3 receptor expression during myogenesis at days 2, 4, and 6; (D) MHC expression during myogenesis at days 2, 4, and 6. The scale bar represents 50 μm . Data are expressed as the mean \pm standard deviation (S.E.M.), and the number of independent experiments is three; $P < 0.01$ compared to day 0 (D0). Typically this is indicated with a *. The qRT-PCR results of the cells of each individual were normalized to the expression at D0, and the expression of D0 is set to 1.




Fig. 2. Immunostaining of H₃ receptor and MHC in differentiated C2C12 cells and adult mid-urethral skeletal muscle tissues. C2C12 cells were grown in 10% FCS-containing DMEM; the medium was then switched to 1% FCS DMEM and differentiated for 6 days. C2C12 cells and mid-urethral skeletal muscle tissues were fixed in 40% formaldehyde solution and stained with the anti-H₃ receptor antibody, anti-MHC antibody, and non-immune rabbit IgG. Upper panel: C2C12 cells, differentiation day 0 (Day 0); middle panel: C2C12, differentiation day 6 (Day 6); lower panel: mid-urethral skeletal muscle tissues. C2C12 cells were counterstained with DAPI and mid-urethral skeletal muscle tissues were counterstained with Mayer's hematoxylin, to reveal cell nuclei (blue). The scale bar represents 50 μ m. (For interpretation of the references to color in this figure legend, the reader is referred to the web version of this article.)

and 279897-fold at days 2, 4, and 6, respectively, compared to day 0 (Fig. 1D). The expression of H₃ receptor, which was initially low in C2C12 myoblasts, also strongly increased with differentiation when compared to day 0; by 26-, 91-, and 182-fold at days 2, 4, and 6, respectively (Fig. 1C).

The immunofluorescence staining of the MHC protein was negative before differentiation (Fig. 2), but was strongly positive at day 6 (Fig. 2). Similarly, immunostaining for the H₃ receptor protein was negative at day 0 (Fig. 2), but was strongly positive at day 6 (Fig. 2).

Human mid-urethral striated muscles showed positive immunostaining for both MHC and H₃ receptor proteins in the filiform-like muscle cells (Fig. 2).

3.3. The H₃ receptor agonist (R)- α -MeHA decreased cytoplasmic Ca²⁺ imaging evoked by electrical stimulation

(R)- α -MeHA of different concentrations was added to stimulate 7 day-differentiated myotubes for 5, 10, and 20 min prior to electrical pacing, and the Ca²⁺ imaging in the cytoplasm was assessed during stimulation (Fig. 3). Incubation with 1 μ M (R)- α -MeHA for 10 or 20 min significantly (55%) decreased the increase of cytoplasmic Ca²⁺ imaging upon electrical pacing. Shorter (5 min) incubation with 100 nM (R)- α -MeHA decreased Ca²⁺ imaging by 45%; longer treatments further increased the decrease-effect when (R)- α -MeHA was over 100 nM. However, (R)- α -MeHA activity in C2C12 cells displayed bell-shaped dynamics: the concentration increase over 1 μ M significantly reduced the decrease-effect of intracellular Ca²⁺ imaging upon electrical stimulation (Fig. 3). The result of (R)- α -MeHA treatment at 30 min is not shown, because obvious decay of the Ca²⁺-labeled Fluo-4 was detected at this time.




Fig. 3. H₃ receptor agonist decreased cytoplasmic Ca²⁺ imaging during electrical stimulation in the skeletal myotubes. C2C12 myotubes, differentiated for 7 days, were loaded with Fluo-4 AM Ca²⁺ indicator dye and were then incubated with the H₃ receptor agonist (R)- α -MeHA at different concentrations (1 nM, 10 nM, 100 nM, 1 μ M, 10 μ M, 100 μ M) and blank control (Elliot medium) for 5, 10, and 20 min before electric pacing. Ca²⁺ imaging was performed as described in Section 2. The data are expressed as the mean \pm standard deviation (S.E.M.), the number of independent experiments is 3, and $P < 0.01$ compared to control is indicated; typically this is indicated with a *. It is $P < 0.05$ compared to 5 min results; typically this is indicated with a #.

4. Discussion

To our knowledge, this is the first investigation of the role of H₃ receptor in skeletal muscle cells. When we first observed H₃ receptor immunostaining in adult skeletal muscle, we hypothesized that H₃ receptor may play a role in skeletal myogenesis or mature skeletal muscle cells. To test this proposal, we assessed H₃ receptor expression kinetics during differentiation of mouse C2C12 myoblast cells. H₃ receptor expression was almost absent in

myoblasts, but increased markedly with myogenesis, suggesting that H₃ receptor mostly functions in differentiated myoblasts that were fused into myotubes. H₃ receptor functional analysis, using an H₃ receptor agonist (R)- α -MeHA, revealed that in fully differentiated 7-day myotubes, H₃ receptor activation decreased Ca²⁺ imaging evoked by electrical stimulation. The lowest (R)- α -MeHA concentration used (1 nM) was below the agonist affinity for H₃ receptor ($pK_i=8.4$) in the brain (Chen et al., 2003 and Li et al., 2014) and had no effect on the cytoplasmic Ca²⁺ imaging under electrical stimulation in our study. On the other hand, the highest (R)- α -MeHA concentration used (100 μ M) was also less active, probably because of combinatorial effects, due to nonspecific activation of other receptors (H₁ receptor or H₂ receptor) on the cell membrane (Chen et al., 2015), which counteracted the response (Leurs et al., 1998), or probably as a self-protective mechanism. The highest inhibitory effect of 1 μ M (R)- α -MeHA, exerted after 10- min or 20 min treatment, was in agreement with a previous pharmacological study on histamine receptor ligands, where (R)- α -MeHA also showed the highest efficacy at 1 μ M (Kottke et al., 2011).

The histamine receptors, including H₃ receptor, are a class of G-protein-coupled receptors. H₃ receptor is coupled to the G_{i/o} proteins, which have prominent effects on Ca²⁺ influx. H₃ receptor-mediated activation of G_{i/o} proteins may cause the activation of phospholipase A₂ (PLA₂), which induces the release of arachidonic acid and the inhibition of the Na⁺/H⁺ exchanger, leading to a decrease in intracellular Ca²⁺ levels involving the impaired entrance of Ca²⁺ through voltage-gated ion channels (Leurs et al., 2005). In cardiac sympathetic nerves, H₃ receptor-mediated inhibition of norepinephrine exocytosis was caused by H₃ receptor-G_i/G_o coupling, and inhibition of adenylyl cyclase activity and cAMP formation, leading to diminished protein kinase A (PKA) activity, and decreased Ca²⁺ influx through voltage-operated Ca²⁺ channels (Leurs et al., 2005). In our experiments, H₃ receptor activation in the differentiated C2C12 myotubes decreased intracellular Ca²⁺ imaging in response to electrical pacing, which is similar to the effect observed in cardiac sympathetic nerve endings.

In mature skeletal muscle cells, the major source of Ca²⁺ is the intracellular Ca²⁺ store in the sarcoplasmic reticulum (SR), which accumulates Ca²⁺ from the cytoplasm in an ATP-dependent manner by the action of Ca²⁺-ATPase (Endo, 2009). Most of this calcium moves back and forth across the SR membrane in cycles of contraction and relaxation. The channel responsible for release from the SR is the ryanodine receptor (RyR). The RyR that mediates the efflux of Ca²⁺ from the SR has a central role in excitation–contraction coupling between sarcolemmal depolarization and SR Ca²⁺ release (Stokes and Wagenknecht, 2000).

In early studies of isolated frog skeletal muscles, catecholamines induced sarcolemmal-depolarized contraction through elevation of cAMP, which also stimulates RyR on the SR, and increased Ca²⁺ flux out from the SR into the cytoplasm (Gonzalez-Serratos et al., 1981). Regulation of Ca²⁺ concentration in the cytoplasm is important in coupling excitation and contraction in skeletal muscle (Emrick et al., 2010). Evidence has suggested that the level of cyclic AMP may be involved in the increase of Ca²⁺ in the cytoplasm (Ong and Steiner, 1977 and Lanner et al., 2010) and is associated with contraction of both cardiac and skeletal muscles (Gonzalez-Serratos et al., 1981). In cultured skeletal myotubes, the activated calcitonin gene-related peptide (CGRP) receptor can positively couple to G_s proteins and activation of adenylyl cyclase, increasing levels of cAMP generation and subsequent protein kinase A (PKA) activation to increase contraction force. During this process, CGRP increases voltage-gated SR Ca²⁺ release within hours, resulting from a quantitatively similar increase in releasable SR Ca²⁺ content (Avila et al., 2007). When

chicken and rat skeletal muscle cells were cultured for 7 days and were then subjected to electrical stimulation for additional 2 days, the ability of these cells to synthesize cAMP was increased by almost two-fold (Young et al., 2000). In our study, electrical stimulation of differentiated C2C12 myotubes may have caused upregulation of cAMP biosynthesis; in this case, H₃ receptor activation may inhibit cAMP elevation and prevent over-contraction. Other studies found histidine decarboxylase activity was very low in normal non exercised muscle (Endo et al., 1998) and mice treated with a H₃ receptor antagonist display no significant effects on prolonged walking endurance (Nijima-Yaoita et al., 2012), suggesting that histamine and H₃ receptor signaling have a limited role on normal muscle physiology. It is the possibility that H₃ receptor is activated only in exercised and/or excited muscle. In addition, we also tried ciproxifan (histamine H₃-receptor antagonist, $pK_i=9.1$ – 9.4) 1 μ M instead of (R)- α -MeHA to do the experiment, and found there was no cytoplasmic Ca²⁺ imaging arise compare to the control. So H₃ receptor blockage might not enhance cell contraction.

In conclusion, we found that the histamine H₃ receptor agonist (R)- α -MeHA can attenuate cytoplasmic Ca²⁺ imaging during electrical stimulation in differentiated C2C12 myotubes, which may facilitate relaxation of cells and prevent over-contraction in electrically stimulated C2C12 myotubes. Attenuation of the cytoplasmic Ca²⁺ imaging may occur via activation of H₃ receptor to induce inhibition of cAMP formation, or activation of PLA₂, release of arachidonic acid, and the subsequent decrease in intracellular Ca²⁺ levels. These effects are most prominent early during myotube maturation. Whether these effects also occur in muscle regeneration remains to be elucidated.

Acknowledgments

The work of Drs. Chen, Stegaev, and Kontinen was supported by Finska Läkaresällskapet, Orion-Farmos Foundation, Sigrid Jusélius Foundation, ORTON Invalid Foundation, HUS evo-grants, Academy of Finland, Center for International Mobility CIMO, the Danish Council for Strategic Research and Regenerative Medicine RNP of the European Science Foundation. The work of Dr Stark was supported by Hesse LOEWE programs OSF, NeFF, and AFA and the TRIP program.

We thank Professor John E. Eriksson of the Turku Center for Biotechnology, Department of Biosciences, University of Turku and Åbo Akademi University, who kindly provided the cells and antibodies.

References

- Avila, G., Aguilar, C.I., Ramos-Mondragón, R., 2007. Sustained CGRP1 receptor stimulation modulates development of EC coupling by cAMP/PKA signalling pathway in mouse skeletal myotubes. *J. Physiol.* 584 (Pt 1), 47–57.
- Cardell, L.O., Edvinsson, L., 1994. Characterization of the histamine receptors in the guinea-pig lung: evidence for relaxant histamine H₃ receptors in the trachea. *Br. J. Pharmacol.* 111, 445–454.
- Chen, J., Liu, C., Lovenberg, T.W., 2003. Molecular and pharmacological characterization of the mouse histamine H₃ receptor. *Eur. J. Pharmacol.* 467, 57–65.
- Chen, Y., Stegaev, V., Kouri, V.P., Sillat, T., Chazot, P.L., Stark, H., Wen, J.G., Kontinen, Y.T., 2015. Identification of histamine receptor subtypes in skeletal myogenesis. *Mol. Med. Rep.* 11, 2624–2630. <http://dx.doi.org/10.3892/mmr.2014.3073>.
- Emrick, M., Sadilek, M., Konoki, K., Catterall, W.A., 2010. Beta-adrenergic-regulated phosphorylation of the skeletal muscle Ca(V)1.1 channel in the fight-or-flight response. *Proc. Natl. Acad. Sci. USA* 107, 18712–18717.
- Endo, M., 2009. Calcium-induced calcium release in skeletal muscle. *Physiol. Rev.* 89, 1153–1176.
- Endo, Y., Tabata, T., Kuroda, H., Tadano, T., Matsushima, K., Watanabe, M., 1998. Induction of histidine decarboxylase in skeletal muscle in mice by electrical stimulation, prolonged walking and interleukin-1. *J. Physiol.* 509 (Pt 2), 587–598.

- Gonzalez-Serratos, H., Hill, L., Valle-Aguilera, R., 1981. Effects of catecholamines and cyclic amp on excitation – contraction coupling in isolated skeletal muscle fibres of the frog. *J. Physiol.* 315, 267–282.
- Ichikawa, A., Sugimoto, Y., Tanaka, S., 2010. Molecular biology of histidine decarboxylase and prostaglandin receptors. *Proc. Jpn. Acad. Ser. B Phys. Biol. Sci.* 86, 848–866.
- Kottke, T., Sander, K., Weizel, L., Schneider, E.H., Seifert, R., Stark, H., 2011. Receptor-specific functional efficacies of alkyl imidazoles as dual histamine H₃/H₄ receptor ligands. *Eur. J. Pharmacol.* 654, 200–208.
- Kubo, Y., Nakano, K., 1999. Regulation of histamine synthesis in mouse CD4⁺ and CD8⁺ T lymphocytes. *Inflamm. Res.* 48, 149–153.
- Lanner, J.T., Georgiou, D.K., Joshi, A.D., Hamilton, S.L., 2010. Ryanodine receptors: structure, expression, molecular details, and function in calcium release. *Cold Spring Harb. Perspect. Biol.* 2, a003996.
- Leurs, R., Bakker, R.A., Timmerman, H., de Esch, I.J., 2005. The histamine H₃ receptor: from gene cloning to H₃ receptor drugs. *Nat. Rev. Drug Discov.* 4, 107–120.
- Leurs, R., Blandina, P., Tedford, C., Timmerman, H., 1998. Therapeutic potential of histamine H₃ receptor agonists and antagonists. *Trends Pharmacol. Sci.* 19, 177–183.
- Li, W.W., Cheng, L.Z., Zou, Z., Tian, M.L., Zhang, H., Raya, A.D., Wang, Y., Shi, X.Y., 2014. (R)-alpha-methylhistamine suppresses inhibitory neurotransmission in hippocampal CA1 pyramidal neurons counteracting propofol-induced amnesia in rats. *CNS Neurosci. Ther.* , <http://dx.doi.org/10.1111/cns.12294>.
- Neuhaus, J., Weimann, A., Stolzenburg, J.U., Dawood, W., Schwalenberg, T., Dorschner, W., 2006. Histamine receptors in human detrusor smooth muscle cells: physiological properties and immunohistochemical representation of subtypes. *World J. Urol.* 24, 202–209.
- Nijima-Yaoita, F., Tsuchiya, M., Ohtsu, H., Yanai, K., Sugawara, S., Endo, Y., Tadano, T., 2012. Roles of histamine in exercise-induced fatigue: favouring endurance and protecting against exhaustion. *Biol. Pharm. Bull.* 35 (1), 91–97.
- Ong, S.H., Steiner, A.L., 1977. Localization of cyclic GMP and cyclic AMP in cardiac and skeletal muscle: immunocytochemical demonstration. *Science* 195, 183–185.
- Pallari, H.M., Lindqvist, J., Torvaldson, E., Ferraris, S.E., He, T., Sahlgren, C., Eriksson, J. E., 2011. Nestin as a regulator of Cdk5 in differentiating myoblasts. *Mol. Biol. Cell* 22, 1539–1549.
- Silver, R.B., Poonwasi, K.S., Seyedi, N., Wilson, S.J., Lovenberg, T.W., Levi, R., 2002. Decreased intracellular calcium mediates the histamine H₃-receptor-induced attenuation of norepinephrine exocytosis from cardiac sympathetic nerve endings. *Proc. Natl. Acad. Sci. USA* 99, 501–506.
- Stokes, D.L., Wagenknecht, T., 2000. Calcium transport across the sarcoplasmic reticulum: structure and function of Ca²⁺-ATPase and the ryanodine receptor. *Eur. J. Biochem.* 267, 5274–5279.
- Szeberenyi, J.B., Pallinger, E., Zsinko, M., Pos, Z., Rothe, G., Orso, E., Szeberenyi, S., Schmitz, G., Falus, A., Laszlo, V., 2001. Inhibition of effects of endogenously synthesized histamine disturbs in vitro human dendritic cell differentiation. *Immunol. Lett.* 76, 175–182.
- Walter, M., Stark, H., 2012. Histamine receptor subtypes: a century of rational drug design. *Front. Biosci. (Schol. Ed.)* 4, 461–488.
- Young, R.B., Bridge, K.Y., Strietzel, C.J., 2000. Effect of electrical stimulation on beta-adrenergic receptor population and cyclic amp production in chicken and rat skeletal muscle cell cultures. *In Vitro Cell. Dev. Biol. Anim.* 36, 167–173.
- Zampeli, E., Tiligada, E., 2009. The role of histamine H₄ receptor in immune and inflammatory disorders. *Br. J. Pharmacol.* 157, 24–33.